


MICROBIAL BIOFILMS



Mahmoud Ghannoum and George A. O'Toole

Editors

MICROBIAL BIOFILMS

Edited by

Mahmoud Ghannoum

Center for Medical Mycology and

Department of Dermatology

Case Western Reserve University School of Medicine

University Hospitals of Cleveland

Cleveland, Ohio

and

George A. O'Toole

Department of Microbiology and Immunology

Dartmouth Medical School

Hanover, New Hampshire



**ASM
PRESS**

Washington, DC

CONTENTS

Contributors ix

Preface xiii

Introduction to Biofilms: Conceptual Themes

George A. O'Toole and Mahmoud Ghannoum

1

1. A Short History of the Development of the Biofilm Concept

J. William Costerton

4

2. Multicellularity and Biofilms

Steven S. Branda and Roberto Kolter

20

3. Fungal Biofilms

Jyotsna Chandra and Mahmoud A. Ghannoum

30

4. Molecular Basis of Biofilm Development by Pseudomonads

Christine M. Toutain, Nicky C. Caiazza, and George A. O'Toole

43

5. Biofilm Development in *Staphylococcus*

Sarah E. Cramton and Friedrich Götz

64

6. Human Oral Bacterial Biofilms

Paul E. Kolenbrander and Robert J. Palmer, Jr.

85

7. Quorum Sensing in Biofilms: Gossip in Slime City

Morten Hentzer, Michael Givskov, and Leo Eberl

118

8. Bacterial Biofilms on Plants: Relevance and Phenotypic Aspects

Guido V. Bloemberg and Ben J. J. Lugtenberg

141

9. Biofilm Structure, Behavior, and Hydrodynamics

L. B. Purevdorj-Gage and P. Stoodley

160

10. A Sticky Business: the Extracellular Polymeric Substance Matrix of Bacterial Biofilms

Melissa Starkey, Kimberly A. Gray, Sung Il Chang, and Matthew R. Parsek

174

11. Genetic Exchange in Biofilms

Dennis G. Cvitkovitch

192

12. Microbial Interactions in Mixed-Species Biofilms

Søren Molin, Tim Tolker-Nielsen, and Susse Kirkelund Hansen

206

13. Modeling Biofilms

Daniel R. Noguera, Gonzalo E. Pizarro, and John M. Regan

222

14. Biofilm Antimicrobial Resistance

Philip S. Stewart, Pranab K. Mukherjee, and Mahmoud A. Ghannoum

250

15. Biofilms and Implant Infections

John G. Thomas, Gordon Ramage, and Jose L. Lopez-Ribot

269

16. Biofilms and Hospital-Acquired Infections

Richard Ebrey, M. Shea Hamilton, Gillian Cairns, and Hilary M. Lappin-Scott

294

17. Biofilms as Reservoirs for Disease

John R. Flanders and Fitnat H. Yildiz

314

18. Role for Biofilms in Infectious Disease

Garth D. Ehrlich, Fen Z. Hu, and J. Christopher Post

332

19. Biofilms in the Water Industry

Bruce E. Rittmann

359

20. Methods of Studying Biofilms

*Robert J. C. McLean, Christa L. Bates, Mary B. Barnes, Christopher L. McGowin,
and Gary M. Aron*

379

21. Concluding Remarks and Future Directions

Roberto Kolter

414

INDEX

- Accessory gene regulator (*agr*), 74–75
- Accumulation-associated protein (AAP),
 Staphylococcus, 72–73
- Accumulation factors, in *Staphylococcus* biofilms,
 69–73
 - accumulation-associated protein (AAP), 72–73
 - biofilm-associated protein (Bap), 73
 - intercellular adhesin locus (*ica*), 71–72
 - polysaccharide intracellular adhesin (PIA), 69–70,
 76
 - PS/A, 70–71
 - slime-associated antigen, 69
 - teichoic acids, 73
- Acinetobacter*, 279–280
 - in mixed-species biofilms, 211–217
 - transformation, 194, 198–199
- Actinobacillus*, 89, 95, 97, 105, 107, 167
- Actinomyces*, 87–88, 91–92, 98, 100
- Aeromonas*
 - biofilm-forming capacity, 317
 - characteristics of organism, 316
 - environmental prevalence, 316–317
 - quorum sensing, 123
- Aggregation, 86–89
- Agrobacterium tumefaciens*, conjugation in, 199
- AHLs (acyl homoserine lactones), 143, 146–150
- Alginate biosynthesis, 177–178, 186
- Animal models, for biofilm study, 389–390
- Antibiotic coating, of medical devices, 288, 302–303
- Antimicrobial locks, 287–288
- Antimicrobial resistance, 250–265, 336–339
 - antimicrobial agents shown to exhibit reduced effi-
 cacy in biofilms, 252
 - EPS and, 184–185
 - factors influencing susceptibility, 254–257
 - fungal biofilms, 282–283
 - antifungal susceptibilities, 253–254, 255
 - drug efflux pumps, role of, 258–259
 - extracellular matrix, role of, 257–258
 - sterol composition, role of, 259–260
 - microorganisms shown to exhibit resistance in
 biofilms, 251
 - protective mechanisms, 260–265
 - altered microenvironmental and slow growth,
 262–263
 - antimicrobial depletion, 260–261
 - multicellular nature of, 264–265
 - persisters, 263–264
 - slow penetration of antimicrobial agents,
 261–262
 - stress responses, 263
- Staphylococcus*, 77–78
- Antimicrobials
 - for indwelling medical devices, 286–288
 - antimicrobial bonded catheters, 288
 - systemic therapy, 287–288
 - techniques for testing, 390–391
- Attachment factors
 - EPS, 181–182
 - Pseudomonas aeruginosa*
 - chaperone/usher system, 51
 - chemical nature of surface, 48–49
 - environment properties, 47–48
 - reversible to irreversible attachment, 49–50
- Staphylococcus*, 66–69
 - autolysin, 67–68
 - capsular polysaccharide adhesin, 67
 - MSCRAMMs (microbial surface components
 recognizing adhesive matrix molecules),
 68–69
 - staphylococcal surface proteins (SSPs), 67
 - teichoic acids, 68

- Attenuated total internal reflectance spectroscopy (ATIR), 401–402
- Autolysin, *Staphylococcus*, 67–68
- Azotobacter*, 177, 178, 180
- Bacillus cereus*, biocontrol by, 146
- Bacillus subtilis*
- conjugation, 201
 - multicellular behaviors, 24, 26
 - transformation, 194–195
- Bacteremia, hospital-acquired, 298
- Bacterial plurality, 335
- Bacteriophages, 201–203
- Batch culture growth techniques, 396–398
- Bifidobacterium*, 100
- Biofertilizers, 141–142
- Biofilm-associated protein (Bap), *Staphylococcus*, 73
- Biofilm Disk Reactor System, 285
- Biofilms
- architecture, 272–273
 - characteristics, 270, 273
 - definition of, 1–2
 - introduction to, 1–3
- Bioreactors, rotating-disk, 397–398
- BOD (biochemical oxygen demand), 359–360, 365–366, 368–370, 372–373
- BODC (biodegradable dissolved organic carbon), 359, 366, 369, 376
- Bottle effect, 6
- Breast prostheses, 340
- Burkholderia*, 25, 48, 123, 209, 352
- Calgary Biofilm Device, 285, 390, 391
- Campylobacter*, 95, 97, 99, 321–322
- Candida albicans*, 30–40, 276, 278, 280, 283, 340, 350
- Candida* biofilms, 30–40
- antimicrobial resistance, 282–283
 - antifungals susceptibilities, 253–254, 255
 - drug efflux pumps, role of, 258–259
 - extracellular matrix, role of, 257–258
 - sterol composition, role of, 259–260
 - central venous catheters, 277, 301
 - clinical relevance of, 30–32
 - catheter-associated, 30–31
 - denture stomatitis, 31
 - voice prostheses, 31–32, 350
 - correlation with pathogenicity, 39
 - dentures, 279
 - endophthalmitis, 347
 - endotracheal tubes, 279–280
 - intracardiac prosthetic devices, 278
 - intrauterine devices, 276
 - mixed with bacteria, 39–40
 - neurosurgical shunts, 279
 - peritoneal dialysis catheters, 278
 - prosthetic joints, 278
 - schematic representation of development, 35
 - urinary catheters, 276
 - visualization of, 38–39
 - in vitro studies on formation of, 32–38
 - optimal growing conditions, 34–38
 - substrate influence on, 32–34
 - voice prostheses, 280
- Candida dubliniensis*, 39
- Candida glabrata*, 31, 39, 276, 278
- Candida krusei*, 39
- Candida parapsilosis*, 39, 278
- Candida pseudotropicalis*, 39
- Candida tropicalis*, 31, 350
- Case mix index, 271
- Catabolic repression control (Crc) protein, 52
- Catheters. *See also* Indwelling medical devices
- antimicrobial bonded, 288
 - central venous catheter (CVC), 31, 276–278, 299–301, 341–342, 346
 - peritoneal dialysis catheters, 278, 347
 - urinary, 9–10, 275–276, 295, 301, 352–354
 - vascular, 341–342
- Cellular automata, approach to modeling biofilms, 232–247
- CA rules, 234–239
- components, 233–234
 - examples, 239–247
 - flowchart of algorithm, 241
 - functionally and structurally heterogeneous biofilm, 244–247
 - functionally homogeneous, structurally heterogeneous biofilm, 239–244
 - microbial decay and detachment, 237
 - microbial distribution within the biofilm, 237–239
 - microbial growth, 237
 - parameter calculation, 240
 - substrate diffusion, 234–236
 - substrate utilization, 236–237
- Central venous catheter (CVC), 31, 276–278, 299–301, 341–342, 346
- Chronic obstructive pulmonary disease (COPD), 352
- Coaggregation mediators, oral bacteria, 86–89
- Colonization, initial in *Pseudomonas aeruginosa*, 44–47
- flagellum-dependent swimming motility, 45–47
 - nature of environment, 44–45
 - phosphate, role of, 45
- Commensal interactions, 209–218
- Competence, 194–199
- Competition in biofilms, 211–218
- Complexity, in biofilms, 16–17
- COMSTAT, 169
- Confocal scanning laser microscopy (CSLM)
- Candida* biofilms, 38–39
 - flow cells, 401
 - introduction into biofilm research, 12
 - mixed-species biofilms, 207, 208
 - overview of methods, 400–401
 - rhizosphere biofilms, 142
- Conjugation, 199–201
- Continuous ambulatory peritoneal dialysis (CAPD), 347

- Continuous culture techniques, 398
 CupA (chaperone/usher protein), 51
 Cyanobacteria, multicellular behaviors, 23
 Cystic fibrosis, 10–12, 186, 294, 295, 305, 352
- Definition, of biofilm, 1–2
Delisea pulchra, 134–135
 Dentures, 31, 279
 Dermal infections, 342
 Detachment and dispersal mechanisms, 56–58, 166–167
 Device-related infections, 299–302. *See also*
 Catheters; Indwelling medical devices
 antibiotic coating of devices, 302–303
 central venous catheters (CVC), 299–301
 history of research, 9–10
 orthopedic devices, 302
 prosthetic heart valves, 295, 301–302
 study methods of device colonization, 390–391
 urinary catheters, 295, 301
- Disinfectants, techniques for testing, 390
 Distributed-genome hypothesis, 335–336
 Drinking water
 distribution pipes, biofilms on, 374–376
 as pathogen source, 314
 Drug efflux pumps, role in antimicrobial resistance in
 fungal biofilms, 258–259
- Eikenella corrodens*, 97
 Electron acceptors, anoxic reduction of, 370–372
 Electron donors, aerobic treatment of inorganic,
 369–370
 Electron microscopy. *See specific methods*
 Endocarditis, 340–341
 native valve, 341
 prosthetic valve, 341
 Endophthalmitis, 347–348
 Endoscopy, 344
 Endotracheal tubes, 279–280, 349–350
Enterobacter agglomerans, 203
Enterococcus
 conjugation in, 199–200, 201
 hospital-acquired infections, 297–298, 304
 Environmental scanning electron microscopy
 (ESEM), 400
 EPS. *See* Extracellular polymeric substances
Erwinia amylovora, 185–186
Erwinia carotovora, 141, 148–149
Erwinia chrysanthemi, 180
Escherichia coli
 continuous culture techniques, 398–399
 horizontal gene transfer, 193, 199–200, 202–203
 scours, 5, 8, 9
Eubacterium, 98, 99
 Evolution in biofilms, 214–218
 Exopolysaccharides, 175–178
 Experiments. *See* Studying biofilms
 Extracellular matrix (ECM), 257–258
 Extracellular polymeric substances (EPS), 174–187,
 361, 364, 379
 chemistry, 164
 composition, 174–181
 exopolysaccharides, 175–178
 nucleic acids, 180–181
 proteins, 178–180
 contributions to biofilm development and func-
 tion, 181–186
 attachment, 181–182
 biofilm structure/architecture, 182–184
 pathogenesis, 185–186
 protection, 184–185
 mechanical properties, 164
- Fibronectin, 36
 Fick's laws, 223
 Fimbriae, 90
 FISH (fluorescence in situ hybridization), 207
 Flagellum-dependent swimming motility, 45–47
 Flow cells, 207–209, 401
 Flowing conditions, community establishment in,
 89–92
 Food-borne diseases, biofilms as reservoirs for,
 321–324
 Campylobacter, 321–322
 Listeria monocytogenes, 322–323
 Salmonella, 323–324
 Fourier transform infrared spectroscopy (FTIR),
 401–402
 Functional genomics, 124–128
 Fungi. *See also* *Candida* biofilms
 bacterium-fungus interactions in the rhizosphere,
 149–150
 biofilms, 30–40, 339–340
 Furanone inhibitors, 135–136
Fusobacterium nucleatum, 89, 97, 106, 306, 307
- GacAS two-component regulatory system, 53
 Gallstones, 306, 343
 Gastrointestinal infections, 342–345
 Gene expression in biofilms, 15–16
 Genetic exchange, 192–203
 conjugation, 199–201
 horizontal gene transfer, overview of, 194
 transduction, 201–203
 transformation, 194–199
 Genomics, 124–133
 Gynecologic infections, 345
- Haemophilus aphrophilus*, 104
Haemophilus influenzae
 endotracheal tube biofilm, 279
 genome plasticity, 336
 otitis media, 350–351
 respiratory infections, 351–352
 transformation, 198, 336

- Heart valves, prosthetic
endocarditis, 340–341
hospital-acquired infections, 295, 301–302
Helicobacter pylori, 324, 343
Hemodialysis, 346–347
Heterocyst, 23
Heterogeneous biofilms, modeling of, 230–232
functionally and structurally heterogeneous
biofilm, 244–247
functionally homogeneous, structurally heteroge-
neous biofilm, 239–244
History, of biofilm concept, 4–17, 162
aquatic ecosystems, nutrient-deprived, 6–9
bottle effect, 6
bovine rumen ecosystem, 4–5
complexity of organization in biofilms, 16–17
device-related biofilms, 9–10
infections, 9–12
modern era, 12–16
biofilm phenotype, 15–16
metabolic heterogeneity, 13–14
physical properties, 12–13
signal control of biofilms, 14–15
structural heterogeneity, 12
universality of biofilms, 6–8
Homeostasis, 161
Homogeneous biofilms, modeling of, 223–228
characteristic reaction times, 226–228
functionally heterogeneous, structurally homo-
geneous biofilm, 228–230
pseudoanalytical solution of steady-state, 228
schematic representation of, 225
Horizontal gene transfer, 192–203
conjugation, 199–201
overview of, 194
transduction, 201–203
transformation, 194–199
Hospital-acquired infections, 294–308
device-related infections, 299–302
antibiotic coating of devices, 302–303
central venous catheters (CVC), 299–301
orthopedic devices, 302
prosthetic heart valves, 295, 301–302
urinary catheters, 295, 301
diagnosis of infection, 302–303
factors affecting biofilm formation, 304–308
host response, 305–306
nutrients, 304–305
pH, 306
surface chemistry and conditioning, 306–308
organisms, 296–298
enterococci, 297–298
staphylococci, 296–297
pathogenesis of attachment, 303–304
sites of infection, 298–299
bacteremia, 298
pneumonia, 299
surgical wound infections, 299
UTI, 298–299
Host response, effect on biofilm formation, 305–306
Hydraulic retention time (HRT), 362
Hydrodynamics, 162–165
Hyphomonas, 181–182
IBET (in biofilm expression technology), 54
Imaging, 400–402. *See also specific imaging methods*
electron microscopy, 400
infrared spectroscopy, 401–402
quantification of biofilm structure, 168–169
COMSTAT, 169
ISA (image structural analysis), 168
SCLM, 400–401
techniques, table of, 395
Implantable cardio defibrillators (ICDs), 270
Indwelling medical devices, 269–288. *See also*
Catheters; Device-related infections
biofilm architecture, 272–273
challenges, 269
clinical chemistry and, 272
cost associated with, 285–286
devices
central venous catheters, 276–278
dentures, 279
endotracheal tubes, 279–280
intracardiac prosthetic devices, 278
intrauterine devices, 276
neurosurgical shunts, 278–279
peritoneal dialysis catheters, 278
prosthetic joints, 278
urinary catheters, 275–276
voice prostheses, 280
diversity of, 271
increase use, 270–271
infection statistics, 274
laboratory detection
history, 281–283
laboratory assessment, 283
in site assessment, 283–284
management and control of infection, 286–288
antimicrobial bonded catheters, 288
systemic antibiotic treatment, 287–288
organisms commonly forming biofilms, 275
susceptibility testing, 284–285
Infections, 332–355
antibiotic resistance, 336–339
breast prostheses, 340
chronic, 333–336
dermatology, 342
device-related, 9–10, 295, 299–302
endocarditis, 340–341
fungal and mixed-kingdom biofilms, 339–340
gastroenterology, 342–345
gynecology, 345
hospital-acquired, 294–308
medical and human cost of treating biofilms,
334

- nephrology, 345–347
 - hemodialysis, 346–347
 - peritoneal dialysis catheters, 347
- neurosurgery, 345
- ophthalmology, 347–348
- orthopedics, 348–349
- otolaryngology, 349–351
 - endotracheal tubes, 349–350
 - otitis media, 350–351
 - voice prosthesis, 339, 350
- phenotypic characteristics of biofilms, 336–339
- probiotics, 339
- pulmonary and respiratory, 351–352
 - chronic obstructive pulmonary disease (COPD), 352
 - cystic fibrosis, 10–12, 294, 295, 305, 352
- theoretical modeling, 334–336
 - bacterial plurality, 335
 - distributed-genome hypothesis, 335–336
- urinary
 - animal models, 389–390
 - catheter-associated, 9–10, 295, 301, 353–354
 - hospital-acquired, 298–299
 - prostheses, 354–355
 - vascular catheters, 341–342
- Infrared spectroscopy, 401–402
- Intercellular adhesin locus (*ica*), *Staphylococcus*, 71–74
- Intracardiac prosthetic devices, 278
- Intrauterine devices, 276
- In vitro models, for biofilm study, 390
- In vivo models, for biofilm study, 388–389
- ISA (image structural analysis), 168
- Joints, prostheses for, 278, 348–349
- Klebsiella*, 261, 279–280
- Laboratory techniques, for studying biofilms, 393–400
 - batch culture growth techniques, 396–398
 - continuous culture techniques, 398
 - maximizing biofilm formation, 398–400
 - microtiter assay, 396–397
 - planktonic cell culture techniques, adaptations of, 396
 - rotating-disk bioreactors, 397–398
 - table of common, 394
- Lactobacillus*, 100, 339, 345, 350
- lap* (large adhesin protein), 50
- Lectins, 179
- Legionella pneumophila*, 324–325
 - biofilm-forming capacity, 318–319
 - characteristics of organism, 317
 - environmental prevalence, 318
- Listeria monocytogenes*
 - biofilm-forming capacity, 323
 - characteristics of organism, 322
 - environmental prevalence, 322
- transduction, 203
- London-van der Waals interactions, 181
- Lyases, 179–180
- Maki technique, 283
- Mathematical description of biofilms. *See* Modeling biofilms
- Mating. *See* Conjugation
- Medical devices. *See* Device-related infections; Indwelling medical devices
- Medically important biofilms, studying, 387–391
 - animal models, 389–390
 - case studies, 389
 - device colonization, 390–391
 - techniques, table of, 387–391
 - testing antibiotics and disinfectants, 390–391
 - in vitro models, 390
 - in vivo models, 388–389
- Methane, anaerobic conversion of BOD to, 372–374
- Microtiter assay for biofilm formation, 396–397
- Mixed-species biofilms, 206–219, 383–384
 - characteristics, 207
 - commensal interactions, 209–218
 - competition in biofilms, 211–218
 - evolution in biofilms, 214–218
 - investigation tools, 207–209
 - programmed development, 219
- Modeling biofilms, 222–247
 - balancing complexity with goals, 232
 - cellular automata approach, 232–247
 - CA rules, 234–239
 - components, 233–234
 - examples, 239–247
 - flowchart of algorithm, 241
 - functionally and structurally heterogeneous biofilm, 244–247
 - functionally homogeneous, structurally heterogeneous biofilm, 239–244
 - microbial decay and detachment, 237
 - microbial distribution within the biofilm, 237–239
 - microbial growth, 237
 - parameter calculation, 240
 - substrate diffusion, 234–236
 - substrate utilization, 236–237
 - chronic disease, theoretical modeling of, 334–336
 - bacterial plurality, 335
 - distributed-genome hypothesis, 335–336
 - heterogeneous biofilm, 230–232
 - functionally and structurally heterogeneous biofilm, 244–247
 - functionally homogeneous, structurally heterogeneous biofilm, 239–244
 - homogeneous biofilm, 223–228
 - characteristic reaction times, 226–228
 - functionally heterogeneous, structurally homogeneous biofilm, 228–230
 - pseudoanalytical solution of steady-state, 228

- Modeling biofilms (*continued*)
 schematic representation of, 225
- Modified Robbins device (MRD), 392–393
- Monoculture studies, studying biofilms in, 381–383
- Moraxella catarrhalis*, 350
- Motility
 flagellum-dependent swimming, 45–47
 pseudomonad, 45–47, 51–52
 role in biofilm formation and structure, 167–168
 swarming, 119, 120
 twitching, 51–52, 167
- MSCRAMMs (microbial surface components recognizing adhesive matrix molecules), 68–69, 303
- Multicellularity, 20–27
 of biofilms, 23–27
 characteristics of, 21–23
 coordination of cell activities, 22–23
 intercellular interactions, 21–22
 terminal differentiation, 26
- Mycobacterium*
 biofilm-forming capacity, 319–320
 characteristics of organism, 319
 environmental prevalence, 319
- Myxococcus xanthus*, multicellular behaviors, 21–22
- Natural environment, growth of biofilms in, 385–387
- Neisseria*, 104, 106, 198
- Nephrology, 345–347
 hemodialysis, 346–347
 peritoneal dialysis catheters, 347
- Neurosurgery, infections associated with, 345
- Neurosurgical shunts, 278–279
- Nucleic acids, in EPS, 180–181
- Nutrients, effect on biofilm formation, 304–305
- Ophthalmic infections, 347–348
- Oral bacterial biofilms, 85–109
 coaggregation mediators, 86–89
 community establishment, 89–92
 future directions, 108–109
 models, abiotic surface
 monospecies biofilms, 101–105
 multispecies biofilms, 105–108
 overview, 85–86
 spatial arrangement, 92–97
 subgingival plaque, 94–97
 supragingival plaque, 92–94
 species composition
 molecular approaches, 97–101
 subgingival, 94–95
 supragingival, 92–94
- Organization, in biofilms, 16–17
- Orthopedic infections, 302, 348–349
- Otitis media, 350–351
- Otolaryngology, infections, 349–351
 endotracheal tubes, 349–350
 otitis media, 350–351
 voice prosthesis, 350
- Oxygen concentration measurements, 337–339
- PCR (polymerase chain reaction), 402–403
- Peptostreptococcus*, 99
- Peritoneal dialysis catheters, 278, 347
- pH, effect on biofilm formation, 306
- Phagocytosis, frustrated, 184
- Phase variation, in *Pseudomonas*, 53–54
- Phenotypic characteristics of biofilms, 336–339
- Phenotypic variation, in *Staphylococcus*, 75–76
- Phosphate, role in pseudomonad biofilm development, 45
- PIA (polysaccharide intracellular adhesin), 69–70, 176–177
- Pili, 51–52, 145–146
- Planktonic cells
 culture techniques, adaptations of, 396
 sessile cells compared to, 8, 9
- Plants, biofilms on, 141–152
 autofluorescent marker proteins as reporters for biofilm visualization, 142–144
 bacterium-fungus interactions, 149–150
 competence and biofilm formation, 144–146
 future perspectives, 151–152
 genome analyses of plant-associated microorganisms, 150–151
 quorum sensing in biofilms, 146–149
 rhizosphere flora, 141
- Plaque
 subgingival, 94–97
 supragingival, 92–94
- Plasmids
 conjugation, 199–201
 transformation, 195–196
- Pneumonia, hospital-acquired, 294–295, 299
- Pollutants
 aerobic treatment of inorganic electron donors, 369–370
 aerobic treatment of organic pollutants, 365–369
 anaerobic conversion of BOD to methane, 372–374
 anoxic reduction of electron acceptors, 370–372
 as biofilm substrates, 359–360
- Polysaccharases, 179–180
- Polysaccharide intracellular adhesin (PIA), 69–70, 176–177
- Porphyromonas gingivalis*, 25, 95, 97, 99, 106–107
- Prevotella*, 87, 95, 99
- Probiotics, 339
- Programmed development, 219
- Proline-rich proteins (PRPs), 90
- Prostheses
 biliary tract, 343
 breast, 340
 heart valves, 295, 301–302, 340–341
 joints, 278, 348–349
 lens, 348

- urinary, 354–355
- voice, 31–32, 280, 339, 350
- Prosthetic joints, 278
- Proteins, in EPS, 178–180
- Proteus*, 120, 276, 279–280, 295, 301, 353
- Pseudomonas aeruginosa*
 - alginate biosynthesis, 177–178, 186
 - antimicrobial resistance, 254–257, 261–264, 336–339
 - attachment
 - chaperone/usher system, 51
 - chemical nature of surface, 48–49
 - environment properties, 47–48
 - reversible to irreversible attachment, 49–50
 - Candida* biofilms, 40
 - catheter-associated UTI, 10
 - colonization, initial, 44–47
 - flagellum-dependent swimming motility, 45–47
 - nature of environment, 44–45
 - phosphate, role of, 45
 - cystic fibrosis, 10–12, 186, 294, 295, 305, 351–352
 - detachment, 56–58
 - biological factors, 57
 - physical mechanics, 57–58
 - DNA extrusion by, 180–181, 336
 - EPS, 177–186
 - gene expression in biofilms, 16
 - genomics, 124–133
 - hollow microcolonies, 167
 - lectins, 179
 - lyase activity, 180
 - macrocolonies, growth from microcolonies, 54–55
 - maintenance of mature biofilms, 55
 - monoculture studies of, 381–383
 - multicellular behaviors, 24–26
 - otorrhea, 351
 - phase variation, 53
 - quorum sensing, 55, 120–123, 124–136
 - rhamnolipids, 56
 - in the rhizosphere, 141, 145, 147–148
 - RpoS, 55–56
 - surface migration, aggregation, and microcolony formation
 - catabolic repression control (Cre) protein, 52
 - GacAS two-component regulatory system, 53
 - IBET (in biofilm expression technology), 54
 - pili and twitching motility, 51–52
 - small colony variants, 53–54
 - virulence factor regulator (Vfr), 52
 - transduction, 202–203
 - water channels in biofilms, 12, 13
- Pseudomonas aureofaciens*, 147–148
- Pseudomonas chlororaphis*, 143, 147
- Pseudomonas fluorescens*
 - biofilm development, 45–51, 56–57
 - lyase, 180
 - phase variation, 53
 - in the rhizosphere, 142–147, 149–150
 - swarming motility, 120
- Pseudomonas oryzae*, 47
- Pseudomonas putida*
 - antimicrobial resistance, 256
 - biofilm development, 45–46, 50–51
 - conjugation in, 201
 - hollow microcolonies, 166–167
 - in mixed-species biofilms, 211–217
 - quorum sensing, 123, 165–166
 - in the rhizosphere, 143–144, 146, 148–150
- Pseudomonas syringae*, 57, 180, 185
- PSTC proteins (pilus/secretion/twitching motility/competence), 198
- Pulmonary and respiratory infections, 351–352
 - chronic obstructive pulmonary disease (COPD), 352
 - cystic fibrosis, 10–12, 294, 295, 305, 351–352
- Quorum sensing, 118–136
 - accessory gene regulator (*agr*), *Staphylococcus*, 74–75
 - bacterial surface translocation, 119–120
 - biofilm structure and, 165–166
 - conjugation, 199
 - functional genomics, 124–128
 - furanone inhibitors, 135–136
 - gram-negative coinhabitants, 274
 - gram-positive oral bacteria, 104
 - history of, 15
 - identification of QS-controlled genes, 128–133
 - inhibitors of, 133–136
 - involvement in biofilm formation, 120–123
 - in natural biofilms, 123–124
 - overview, 118–119
 - Pseudomonas aeruginosa*, 55
 - in rhizosphere biofilms, 146–149
 - RpoS effect on, 55
 - swarming motility, 119, 120
 - transformation and, 194–196
- Ralstonia solanacearum*, 141, 145, 147, 186
- Recombination, 195
- Regulation of biofilm formation, in *Staphylococcus*, 73–75
 - accessory gene regulator (*agr*), 74–75
 - alternative sigma factor B (*sigB*), 74
 - autolysis-related locus, 75
 - intercellular adhesion regulator (*IcaR*), 73–74
- Renal disease, end-stage (ESRD), 345–346
- Research. *See* History; Studying biofilms
- Reservoirs for disease, 314–326
 - food-borne diseases, 321–324
 - Campylobacter*, 321–322
 - Listeria monocytogenes*, 322–323
 - Salmonella*, 323–324
 - overview, 314–316
 - water-borne diseases, 316–321
 - Aeromonas*, 316–317
 - Legionella pneumophila*, 317–319

Reservoirs for disease (continued)

Mycobacterium, 319–320*Vibrio cholerae*, 320–321

Rhamnolipids, 56

Rhizobium spp., 142–143, 147

Rhizosphere

bacterium-fungus interactions, 149–150

competence and biofilm formation, 144–146

flora, 141

quorum sensing in biofilms, 146–149

Robbins device, 392–393

Rotating-disk bioreactors, 397–398

Rothia dentocariosa, 32, 350

RpoS, 55–56

Saccharomyces cerevisiae, 39

SadARS system, 55

Salmonella

antimicrobial resistance, 254

biofilm-forming capacity, 323–324

biofilms on gallstones, 306

characteristics, 323

environmental prevalence, 323

Scanning electron microscopy (SEM)

Candida biofilms, 33, 38

catheter-associated biofilm, 10

overview of methods, 400

plaque, 93, 95

rhizosphere biofilms, 142

ventricular-peritoneal shunts, 345

Scanning transmission electron microscopy (STEM), 400

SCLM (scanning confocal laser microscopy).

See Confocal scanning laser microscopy (CSLM)

Serratia biofilms, 12, 119–120, 123Sigma factor B (*sigB*), 74

Signal autoinducer 2, 25

Signal control of biofilms, 14–15

Silicone breast prostheses, 340

Slime-associated antigen, 69

Small colony variants, in *Pseudomonas*, 53–54

Solids retention time (SRT), 362, 370

Staphylococcus

accumulation factors, 69–73

accumulation-associated protein (AAP), 72–73

biofilm-associated protein (Bap), 73

intercellular adhesin locus (*ica*), 71–72

polysaccharide intracellular adhesin (PIA), 69–70, 76

PS/A, 70–71

slime-associated antigen, 69

teichoic acids, 73

biofilm development, 64–78

CoNS (coagulase-negative staphylococci), 277,

296, 298, 300, 303, 342, 345, 348

environmental conditions, 76–78

antibiotics, 77–78

ethanol, 77

iron, 77

magnesium, 77

osmotic stress, 77

oxygen, 76–77

hospital-acquired infections, 295–304, 306–307

phenotypic variation, 75–76

primary attachment factors, 66–69

autolysin, 67–68

capsular polysaccharide adhesin, 67

MSCRAMMs (microbial surface components recognizing adhesive matrix molecules), 68–69

staphylococcal surface proteins (SSPs), 67

teichoic acids, 68

regulation of biofilm formation, 73–75

accessory gene regulator (*agr*), 74–75alternative sigma factor B (*sigB*), 74

autolysis-related locus, 75

intercellular adhesion regulator (*IcaR*), 73–74

in vivo models, 78

Staphylococcus aureus

antimicrobial resistance, 262

artificial joint infections, 349

biofilm development

accumulation factors, 70–72

environmental conditions, 76–77

phase variation, 76

primary attachment factors, 66, 68–69

regulation, 74–75

study of, 65–66

in vivo models, 78

central venous catheter, 277

dermal infections, 342

endotracheal tube biofilm, 279

gynecologic infections, 345

hospital-acquired infections, 295–299, 301–304, 306–307

methicillin resistant (MRSA), 295, 296–299, 301–302

urinary catheter-associated infection, 295

intracardiac prosthetic devices, 278

peritoneal dialysis catheters, 278

peritonitis, 345

polysaccharide intracellular adhesin (PIA), 176

transduction, 202

Staphylococcus caprae, 68, 71*Staphylococcus carnosus*, 71, 176*Staphylococcus epidermidis*

antimicrobial resistance, 256

artificial joint infections, 349

biofilm development, 64–78

accumulation factors, 69–73

environmental conditions, 76–78

phenotypic variation, 75–76

primary attachment factors, 66–69

regulation, 73–75

study of, 65–66

- in vivo models, 78
- Candida* biofilms, 40
- graft infections, 304
- hollow microcolonies, 167
- peritonitis, 345
- polysaccharide intracellular adhesin (PIA), 176
- prosthetic heart valve-associated infection, 295, 341
- Staphylococcus lugdunensis*, 298
- Staphylococcus saprophyticus*, 68, 71
- Stenotrophomonas maltophilia*, 280
- Stents, 343–344
- Sterol composition, role of antimicrobial resistance in fungal biofilms, 259–260
- Streptococcus constellatus*, 100
- Streptococcus gordonii*
 - oral biofilms, 86–88, 90–91, 93, 101, 103, 105
 - signal autoinducer 2, 25
 - transformation, 194–195, 197, 201
- Streptococcus mitis*, 86, 88, 94, 104
- Streptococcus mutans*
 - Candida* biofilms, 40
 - oral biofilms, 100, 102–104, 106
 - polysaccharase, 180
 - transformation, 194–197, 199
- Streptococcus oralis*, 86–88, 91, 94, 106
- Streptococcus parasanguinis*, 100, 104
- Streptococcus pneumoniae*
 - antimicrobial resistance, 256
 - otitis media, 350–351
 - transformation, 194–198
- Streptococcus salivarius*, 100, 104
- Streptococcus sanguinis*
 - fluorescent staining of biofilm, 306, 307
 - oral biofilms, 86, 88, 94, 106
- Streptococcus thermophilus*, 350
- Streptomyces coelicolor*, multicellular behaviors, 23
- Structure, biofilm, 160–169
 - detachment and dispersal mechanisms, 166–167
 - EPS (extracellular polymeric substance), 164
 - factors relating to, 162–164
 - historical aspects, 162
 - hollow microcolonies, 166–167
 - motility, role in biofilm formation and structure, 167–168
 - quantification of, 168–169
 - COMSTAT, 169
 - ISA (image structural analysis), 168
 - quorum sensing, 165–166
- Studying biofilms, 379–403
 - choice of microorganisms, 380–384
 - examples, 381
 - mixed cultures, 383–384
 - monoculture studies, 381–383
 - future directions, 414–416
 - genetics, 396, 402–403
 - growth of biofilms, 383–400
 - industrial applications, 391–393
 - laboratory techniques, common, 393–400
 - medically important biofilms, 387–391
 - in natural environment, 385–387
 - techniques, table of examples, 386
 - imaging, 400–402
 - electron microscopy, 400
 - infrared spectroscopy, 401–402
 - SCLM, 400–401
 - techniques, table of, 395
 - industrial applications, 391–393
 - Robbins device, 392–393
 - table of, 392
 - laboratory techniques, 393–400
 - batch culture growth techniques, 396–398
 - continuous culture techniques, 398
 - maximizing biofilm formation, 398–400
 - microtiter assay, 396–397
 - planktonic cell culture techniques, adaptations of, 396
 - rotating-disk bioreactors, 397–398
 - table of common, 394
 - medically important biofilms, 387–391
 - animal models, 389–390
 - case studies, 389
 - device colonization, 390–391
 - techniques, table of, 387–391
 - testing antibiotics and disinfectants, 390–391
 - in vitro models, 390
 - in vivo models, 388–389
- Surface chemistry and conditioning, effect on biofilm formation, 306–308
- Surface translocation, 119–120
- Surgical wound infections, hospital-acquired, 299
- Susceptibility testing, 284–285
- Swarming motility, 119, 120
- Tannerella forsythensis*, 99
- Teichoic acids, 68, 73
- Total joint replacement prostheses, 348–349
- Total Kjeldahl Nitrogen (TKN), 369–370
- Transduction, 201–203
- Transformation, 194–199
- Transmission electron microscopy (TEM)
 - cystic fibrosis pneumonia, 11
 - of *E. coli* scours, 5, 7, 8
 - overview of methods, 400
 - of rumen contents, 4–6
 - supragingival plaque, 92
 - surgical staple-associated biofilm, 12
- Transposon, conjugative, 201
- Treponema*, 95, 98, 99, 107
- Twitching motility, 51–52, 167
- Type IV pili (Tfp), 51–52
- Urinary catheters
 - biofilms, 9–10, 275–276, 353–354
 - hospital-acquired infections, 295, 301
- Urinary prostheses, 354–355

Urinary tract infection (UTI)

- animal models, 389–390
- catheter-associated, 9–10, 276, 295, 301, 352–354
- hospital-acquired, 298–299

Vascular grafts, 341–342

Veillonella, 98, 100

Ventilator-associated pneumonia, 279–280, 286

Ventricular-peritoneal shunts, 344–345

Vibrio, conjugation in, 200*Vibrio cholerae*, 325

- biofilm-forming capacity, 320–321
- characteristics of organism, 320
- environmental prevalence, 320, 344
- EPS, 181, 183–184
- outbreaks, 344

Vibrio harveyi, 15, 102, 107

Virulence factor regulator (Vfr), 52

Voice prostheses, 31–32, 280, 339, 350

Water-borne diseases, biofilms as reservoirs for, 316–321

Aeromonas, 316–317*Legionella pneumophila*, 317–319*Mycobacterium*, 319–320*Vibrio cholerae*, 320–321

Water channels in biofilms, 12, 13

Water industry, biofilms in, 359–376

fundamental characteristics of systems, 359–365

concentration gradients, 362–363

fixed architecture, 364–365

physical structure of biofilm, 361

pollutants as substrates, 359–360

retention time of large solids, 362

substrate flux, 363–364

substratum features, 360–361

unwanted biofilms, 374–376

drinking-water distribution, 374–376

industrial process waters, 376

water treatment processes, 365–374

aerobic treatment of inorganic electron donors, 369–370

aerobic treatment of organic pollutants, 365–369

anaerobic conversion of BOD to methane, 372–374

anoxic reduction of electron acceptors, 370–372

Yersinia pestis, 343